Welcome to our dedicated page for Genasys SEC filings (Ticker: GNSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genasys Inc. (NASDAQ: GNSS) SEC filings, offering investors and analysts a centralized view of the company’s regulatory disclosures. Genasys is a Protective Communications company in the audio and video equipment manufacturing industry, and its filings with the U.S. Securities and Exchange Commission document material events, financial performance, and governance matters related to GNSS stock.
Genasys files annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, segment information for its Hardware and Software businesses, and discussions of risk factors and operations. Current reports on Form 8-K are used to disclose specific material events. For example, recent 8-K filings have addressed financial results for a fiscal quarter and changes in executive roles, such as the retirement of a Chief Financial Officer and the appointment of an interim Chief Financial Officer, Treasurer and Secretary.
Through this filings page, users can review documents related to revenue contributions from hardware and software, gross margins, operating expenses, and non-GAAP measures such as adjusted EBITDA, as reported by the company. Filings also identify the company’s listing on The Nasdaq Stock Market under the ticker symbol GNSS and provide details on board and management changes, compensation arrangements, and other corporate actions.
Stock Titan’s platform enhances these SEC filings with AI-powered summaries that explain key points in plain language, highlight important trends, and help users interpret complex sections of lengthy reports such as Forms 10-K and 10-Q. Real-time updates from the SEC’s EDGAR system, along with access to Form 4 and other ownership-related filings, allow readers to monitor material disclosures and insider-related information associated with Genasys Inc. more efficiently.
Genasys Inc. director Lawrence F. Hagenbuch received an equity grant of 48,498 restricted stock units (RSUs), each representing one share of Genasys common stock. The RSUs were granted as part of the company’s standard compensation for non-employee directors and carry no cash exercise price.
The RSUs vest on the earlier of the company’s 2027 annual shareholder meeting or a change of control. After this grant, Hagenbuch holds 48,498 shares or share-settled units directly, aligning his compensation further with shareholder equity performance.
Genasys Inc. director Lawrence F. Hagenbuch has filed a Form 3, which is the initial statement of his beneficial ownership as a company insider. The provided information lists his role as a director but does not show any specific share holdings or report any transactions.
Genasys Inc. has appointed Larry Hagenbuch to its Board of Directors and named him Chair of the Audit Committee. He will serve until the next annual stockholder meeting and brings more than two decades of financial, operational, and restructuring experience.
Hagenbuch is an operating partner at Crossplane Capital and previously led interim management and turnaround engagements at Huron Consulting, following leadership roles at GE, GE Capital, and other firms. He has chaired or served on audit committees at several public companies, adding deep audit and governance expertise.
As part of his election, he received restricted stock units on the same terms as other non-employee directors and will be compensated under existing director practices. A press release announcing his appointment is furnished as an exhibit, and the company reiterates its focus on Protective Communications solutions deployed worldwide.
Dodd William H reported acquisition or exercise transactions in this Form 4 filing.
Genasys Inc. director William H. Dodd received an equity award of 47,620 shares of common stock in the form of restricted stock units. The grant was a compensation-related award at no cash purchase price. Following this award, he holds 176,783 shares of common stock directly.
The RSUs vest upon the earlier of the company’s 2027 annual shareholder meeting or a change of control event. Each unit represents a contingent right to receive one share of Genasys common stock, settled solely in shares rather than cash.
Fugate William Craig reported acquisition or exercise transactions in this Form 4 filing.
Genasys Inc. director William Craig Fugate received a grant of 47,620 restricted stock units (RSUs) of common stock as equity compensation, with no cash purchase price. The RSUs vest upon the earlier of the company’s 2027 annual shareholder meeting or a change of control event. Each RSU represents a contingent right to one share of Genasys common stock, to be settled solely in shares. Following this award, Fugate directly holds 115,821 shares of the company’s common stock.
Malhotra R. Rimmy reported acquisition or exercise transactions in this Form 4 filing.
Genasys Inc. director R. Rimmy Malhotra reported receiving an award of 47,620 restricted stock units (RSUs) of common stock. These RSUs vest upon the earlier of the company’s 2027 annual shareholder meeting or a change of control, and each RSU represents one share settled solely in stock, with no cash purchase price.
After this grant, Malhotra holds 196,285 shares directly. The filing also lists indirect holdings of 1,628,495 Genasys shares owned by Nicoya Fund, LLC and 300 shares owned by Nicoya Genasys‑SPV LLC, entities managed through Nicoya Capital, LLC.
Genasys Inc. director Susan Lee Schmeiser reported receiving a grant of 47,620 shares of common stock in the form of restricted stock units at no cash cost. These RSUs vest upon the earlier of the company’s 2027 annual shareholder meeting or a change of control event. Each RSU converts into one share of common stock, deliverable only in shares. Following this grant, her reported direct holdings total 193,256 shares of Genasys common stock.
Genasys Inc. reported the results of its 2026 Annual Meeting of Stockholders. There were 45,212,311 common shares outstanding and eligible to vote as of January 21, 2026, and 25,083,917 shares were represented in person or by proxy at the March 17, 2026 meeting.
All five director nominees were elected to one-year terms. Support for four nominees ranged from about 13.1 million to 13.9 million votes, while Susan Lee Schmeiser received 11,326,368 votes for and 4,044,163 withheld. Each director election had 9,713,386 broker non-votes.
Stockholders also ratified the appointment of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 21,419,235 votes for, 2,005,498 against and 1,659,184 abstentions. On an advisory, non-binding basis, executive compensation was approved with 8,844,760 votes for, 5,107,733 against, 1,418,038 abstentions and 9,713,386 broker non-votes.
Genasys Inc. director William H. Dodd reported open-market purchases of a total of 25,457 shares of common stock. The transactions were completed on February 18 and 19, 2026 at prices between $1.97 and $1.98 per share. Following these purchases, he directly holds 129,163 shares.
Genasys Inc. reported a sharp improvement in quarterly results for the three months ended December 31, 2025. Total revenues rose to $17,065 from $6,940 a year earlier, driven mainly by product sales increasing to $14,261 from $4,144. Net loss narrowed to $817, or $0.02 per share, compared with a loss of $4,078, or $0.09 per share.
Cash, cash equivalents and restricted cash increased to $10,871, helped by strong operating cash flow of $7,200. Contract liabilities grew to $35,337, with $25,289 of remaining performance obligations and $25,038 in customer deposits tied to the Puerto Rico Early Warning System project, most expected to convert to revenue within 12 months.